Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer

详细信息    查看全文

• 作者：Guanglei Chen ; Gang Li ; Minna Luo ; Xiaofei Wei ; Dan Wang ; Hao Zhang…
• 关键词：Breast cancer ; SPRR1A ; Progesterone receptor positive
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：36
• 期：4
• 页码：2601-2605
• 全文大小：259 KB
• 参考文献：1.Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37 Suppl 8:S4-6.View Article PubMed
  2.Joensuu H, Kellokumpu-Lehtinen PL, Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-0.View Article PubMed
  3.De Heller-Milev M, Huber M, Panizzon R. Expression of small proline rich proteins in neoplastic and inflammatory skin diseases. Br J Dermatol. 2000;143(4):733-0.View Article PubMed
  4.Fujimoto W, Nakanishi G, Arata J, Jetten AM. Differential expression of human cornifin alpha and beta in squamous differentiating epithelial tissues and several skin lesions. J Invest Dermatol. 1997;108(2):200-.View Article PubMed
  5.Bonilla IE, Tanabe K, Strittmatter SM. Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci. 2002;22(4):1303-5.PubMed
  6.Morris JS, Davies CR, Griffiths MR, Page MJ. Proteomic analysis of mouse mammary terminal end buds identifies axonal growth cone proteins. Proteomics. 2004;4(6):1802-0.View Article PubMed
  7.Morris JS, Stein T, Pringle MA, Davies CR. Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland. J Cell Physiol. 2006;206(1):16-4.View Article PubMed
  8.Starkey ML, Davies M, Yip PK, Carter LM. Expression of the regeneration-associated protein SPRR1A in primary sensory neurons and spinal cord of the adult mouse following peripheral and central injury. J Comp Neurol. 2009;513(1):51-8.View Article PubMed Central PubMed
  9.Mercier I, Casimiro MC, Zhou J, Wang C. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol. 2009;174(4):1172-0.View Article PubMed Central PubMed
  10.Marklund N, Fulp CT, Shimizu S, Puri R, McMillan A, Strittmatter SM. Selective temporal and regional alterations of Nogo-A and small proline-rich repeat protein 1A (SPRR1A) but not Nogo-66 receptor (NgR) occur following traumatic brain injury in the rat. Exp Neurol. 2006;197(1):70-3.View Article PubMed Central PubMed
  11.Zhang H, Gao J, Zhao Z1, Li M, Liu C. Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study. BMC Cancer. 2014;14:333.View Article PubMed Central PubMed
  12.Bonilla IE, Tanabe K, Strittmatter SM. Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci. 2002;22(4):1303-5.PubMed
  
• 作者单位：Guanglei Chen (1) (2)
  Gang Li (3)
  Minna Luo (4)
  Xiaofei Wei (1)
  Dan Wang (1)
  Hao Zhang (1)
  Xinhan Zhao (4)
  Bo Chen (2)
  Caigang Liu (1)
  
  1. Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, 116023, China
  2. Breast Surgery, The First Hospital of China Medical University, Shenyang, 110001, China
  3. Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China
  4. Department of Oncology, The First Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, 710061, China
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Small proline-rich repeat protein 1A (SPRR1A) is a marker for terminal squamous cell differentiation. Previous studies showed that SPRR1A expression increases in squamous cell carcinoma of the skin, but decreases in esophageal squamous cell carcinoma. This study focuses on the expression of SPRR1A protein in breast cancers (BCs) in China. A total of 111 patients with histologically confirmed BC, who underwent radical surgery between January 2006 and September 2007 in China Medical University, were enrolled. The relationship between SPRR1A expression and clinicopathological factors as well as BC prognoses was also determined. Overall, SPRR1A expression was detected in more than half of the BC specimens by immunohistochemistry (56/111, 53.8?%), but there was no significant difference between age groups (?0 vs. <50?years) in terms of SPRR1A expression (P--.915), as well as no differences between SPRR1A expression and the clinical stage (0–I vs. II–III) or nodal status (P--.234 and 0.632, respectively). Moreover, human epidermal growth factor receptor 2 overexpression was not correlated with SPRR1A expression, whereas Ki67 was associated with SPRR1A expression (P--.155 and 0.028, respectively). Interestingly, SPRR1A expression was significantly associated with progesterone receptor-positive (P--.010) rather than estrogen receptor-positive (0.778) BCs. The 5-year survival rate in patients did not differ with the presence or absence of SPRR1A expression (P--.753), whereas the combination of SPRR1A expression, progesterone receptor status, and menopausal status allowed identification of a subgroup of BC patients with a good long-term prognosis. Thus, the SPRR1A status might play an important role in the prognosis of postmenopausal breast carcinoma patients, especially that of progesterone receptor-positive subgroups.